SAMN03290901
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.400
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- APICAL_SURFACE+0.300
- COMPLEMENT+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- PANCREAS_BETA_CELLS+0.300
- XENOBIOTIC_METABOLISM+0.300
- APICAL_JUNCTION+0.200
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MITOTIC_SPINDLE-0.400
- PROTEIN_SECRETION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- UV_RESPONSE_DN-0.400
- MYC_TARGETS_V1-0.300
- ANGIOGENESIS-0.200
- MYC_TARGETS_V2-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290893 | — | — | 0.868 |
| 2 | SAMN03290919 | — | — | 0.842 |
| 3 | SRR1433600 | GTEX | — | 0.834 |
| 4 | SRR1419148 | GTEX | — | 0.819 |
| 5 | SAMN03290907 | — | — | 0.818 |
| 6 | MDT-AP-0720 | Med | Medulloblastoma | 0.818 |
| 7 | SRR1080172 | GTEX | — | 0.807 |
| 8 | ERR2598280 | fetal | fetal | 0.799 |
| 9 | TCGA-BH-A5J0-01A-11R-A27Q-07 | — | B | 0.794 |
| 10 | SAMN03290904 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |